Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Operating Leases (2019 - 2025)

UroGen Pharma (URGN) has disclosed Operating Leases for 7 consecutive years, with $6.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases rose 270.36% year-over-year to $6.1 million, compared with a TTM value of $6.1 million through Dec 2025, up 270.36%, and an annual FY2025 reading of $6.1 million, up 270.36% over the prior year.
  • Operating Leases was $6.1 million for Q4 2025 at UroGen Pharma, down from $6.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $6.2 million in Q3 2025 and bottomed at $277000.0 in Q1 2022.
  • Average Operating Leases over 5 years is $1.9 million, with a median of $1.2 million recorded in 2024.
  • The sharpest move saw Operating Leases plummeted 82.45% in 2021, then skyrocketed 755.96% in 2023.
  • Year by year, Operating Leases stood at $398000.0 in 2021, then soared by 298.49% to $1.6 million in 2022, then plummeted by 46.78% to $844000.0 in 2023, then surged by 95.85% to $1.7 million in 2024, then soared by 270.36% to $6.1 million in 2025.
  • Business Quant data shows Operating Leases for URGN at $6.1 million in Q4 2025, $6.2 million in Q3 2025, and $3.4 million in Q2 2025.